MXPA01008805A - Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or h2 - Google Patents
Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or h2Info
- Publication number
- MXPA01008805A MXPA01008805A MXPA/A/2001/008805A MXPA01008805A MXPA01008805A MX PA01008805 A MXPA01008805 A MX PA01008805A MX PA01008805 A MXPA01008805 A MX PA01008805A MX PA01008805 A MXPA01008805 A MX PA01008805A
- Authority
- MX
- Mexico
- Prior art keywords
- optically pure
- proton pump
- pump inhibitor
- patient
- receptor antagonist
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 239000000612 proton pump inhibitor Substances 0.000 title claims description 66
- 230000003482 proton pump inhibitor Effects 0.000 title claims description 65
- OMLDMGPCWMBPAN-YPMHNXCESA-N norcisapride Chemical compound CO[C@H]1CNCC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC OMLDMGPCWMBPAN-YPMHNXCESA-N 0.000 title claims description 56
- 229940077718 Proton pump inhibitors for peptic ulcer and GORD Drugs 0.000 title description 12
- 208000008665 Gastrointestinal Disease Diseases 0.000 claims abstract description 39
- 150000001875 compounds Chemical class 0.000 claims abstract description 37
- 230000002265 prevention Effects 0.000 claims abstract description 28
- 108091005523 5-HT4 receptors Proteins 0.000 claims abstract description 15
- 108091005518 5-HT3 receptors Proteins 0.000 claims abstract description 13
- 102000035257 5-HT3 receptors Human genes 0.000 claims abstract description 13
- 108010083204 Proton Pumps Proteins 0.000 claims abstract description 12
- 102000006270 Proton Pumps Human genes 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims description 55
- 239000011780 sodium chloride Substances 0.000 claims description 55
- 230000001225 therapeutic Effects 0.000 claims description 50
- DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 claims description 49
- 229960005132 cisapride Drugs 0.000 claims description 46
- 102000005962 receptors Human genes 0.000 claims description 41
- 108020003175 receptors Proteins 0.000 claims description 41
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims description 38
- 239000002207 metabolite Substances 0.000 claims description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- MJIHNNLFOKEZEW-UHFFFAOYSA-N Dexlansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 229960000381 omeprazole Drugs 0.000 claims description 20
- 239000002464 receptor antagonist Substances 0.000 claims description 20
- 229960005019 pantoprazole Drugs 0.000 claims description 18
- SUBDBMMJDZJVOS-UHFFFAOYSA-N Esomeprazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 16
- 230000002496 gastric Effects 0.000 claims description 16
- XUFQPHANEAPEMJ-UHFFFAOYSA-N Famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 15
- 208000009471 Gastroesophageal Reflux Diseases 0.000 claims description 15
- 206010017885 Gastrooesophageal reflux disease Diseases 0.000 claims description 15
- 201000006860 gastroesophageal reflux disease Diseases 0.000 claims description 15
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 229960003174 lansoprazole Drugs 0.000 claims description 15
- 201000006549 dyspepsia Diseases 0.000 claims description 14
- 229960000620 Ranitidine Drugs 0.000 claims description 13
- VMXUWOKSQNHOCA-LCYFTJDESA-N Ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 13
- 206010047700 Vomiting Diseases 0.000 claims description 13
- 229960004157 rabeprazole Drugs 0.000 claims description 13
- 229960001380 Cimetidine Drugs 0.000 claims description 12
- CCGSUNCLSOWKJO-UHFFFAOYSA-N Cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 12
- 229960001596 Famotidine Drugs 0.000 claims description 12
- SGXXNSQHWDMGGP-IZZDOVSWSA-N Nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 claims description 12
- 230000003042 antagnostic Effects 0.000 claims description 11
- 239000005557 antagonist Substances 0.000 claims description 11
- 230000004064 dysfunction Effects 0.000 claims description 11
- 229960004872 Nizatidine Drugs 0.000 claims description 10
- 230000005176 gastrointestinal motility Effects 0.000 claims description 9
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3R)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims description 8
- 206010020601 Hyperchlorhydria Diseases 0.000 claims description 8
- 210000002784 Stomach Anatomy 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 8
- 206010010774 Constipation Diseases 0.000 claims description 7
- 206010063655 Erosive oesophagitis Diseases 0.000 claims description 7
- 206010061459 Gastrointestinal ulcer Diseases 0.000 claims description 7
- 230000001575 pathological Effects 0.000 claims description 7
- CMZHQFXXAAIBKE-UHFFFAOYSA-N 5'-hydroxyomeprazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(CO)C(OC)=C1C CMZHQFXXAAIBKE-UHFFFAOYSA-N 0.000 claims description 6
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 6
- 102100004996 ATP12A Human genes 0.000 claims description 5
- 206010000059 Abdominal discomfort Diseases 0.000 claims description 5
- 208000001288 Gastroparesis Diseases 0.000 claims description 5
- 206010021518 Impaired gastric emptying Diseases 0.000 claims description 5
- 229960005343 Ondansetron Drugs 0.000 claims description 5
- 206010054048 Postoperative ileus Diseases 0.000 claims description 5
- 201000002146 gastrointestinal system disease Diseases 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 208000003243 Intestinal Obstruction Diseases 0.000 claims description 3
- 201000010874 syndrome Diseases 0.000 claims description 2
- GRHYHJAAOJVRSZ-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2N=C3[CH]C(OC(F)F)=CC=C3N=2)=C1OC GRHYHJAAOJVRSZ-UHFFFAOYSA-N 0.000 claims 12
- SXTZYIWTRUTYCY-UHFFFAOYSA-N Rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2N=C3[CH]C=CC=C3N=2)=C1C SXTZYIWTRUTYCY-UHFFFAOYSA-N 0.000 claims 9
- IDCLTMRSSAXUNY-UHFFFAOYSA-N 5-hydroxylansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC(O)=CC=C2N1 IDCLTMRSSAXUNY-UHFFFAOYSA-N 0.000 claims 4
- SUBDBMMJDZJVOS-XMMPIXPASA-N (R)-omeprazole Chemical compound C([S@@](=O)C=1NC2=CC=C(C=C2N=1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-XMMPIXPASA-N 0.000 claims 2
- 229960004770 esomeprazole Drugs 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 108020000629 histamine receptor H2 Proteins 0.000 claims 1
- 102000003710 Histamine H2 Receptors Human genes 0.000 abstract description 9
- 108090000050 Histamine H2 Receptors Proteins 0.000 abstract description 9
- 239000003814 drug Substances 0.000 description 40
- 239000004480 active ingredient Substances 0.000 description 25
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 24
- 230000027455 binding Effects 0.000 description 22
- 239000003826 tablet Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 17
- 239000007788 liquid Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 230000002354 daily Effects 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 229940079593 drugs Drugs 0.000 description 9
- 239000000018 receptor agonist Substances 0.000 description 9
- 102000034451 ATPases Human genes 0.000 description 8
- 108091006096 ATPases Proteins 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 210000004027 cells Anatomy 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 230000002194 synthesizing Effects 0.000 description 8
- 210000004379 Membranes Anatomy 0.000 description 7
- 229940076279 Serotonin Drugs 0.000 description 7
- 150000003936 benzamides Chemical class 0.000 description 7
- 238000007906 compression Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000000144 pharmacologic effect Effects 0.000 description 7
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 7
- 210000004211 Gastric Acid Anatomy 0.000 description 6
- 229940077716 Histamine H2 receptor antagonists for peptic ulcer and GORD Drugs 0.000 description 6
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 6
- 231100000494 adverse effect Toxicity 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 230000000051 modifying Effects 0.000 description 6
- IQPSEEYGBUAQFF-UHFFFAOYSA-N pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 210000002464 Muscle, Smooth, Vascular Anatomy 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- 208000000718 Duodenal Ulcer Diseases 0.000 description 4
- 210000003238 Esophagus Anatomy 0.000 description 4
- 210000004051 Gastric Juice Anatomy 0.000 description 4
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 208000007107 Stomach Ulcer Diseases 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 230000002255 enzymatic Effects 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000000968 intestinal Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000007905 soft elastic gelatin capsule Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- -1 4-fluorophenoxy Chemical group 0.000 description 3
- 102000037085 5-hydroxytryptamine receptor family Human genes 0.000 description 3
- 108091019276 5-hydroxytryptamine receptor family Proteins 0.000 description 3
- 206010003119 Arrhythmia Diseases 0.000 description 3
- 206010007521 Cardiac arrhythmias Diseases 0.000 description 3
- 210000000170 Cell Membrane Anatomy 0.000 description 3
- 210000003169 Central Nervous System Anatomy 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- MFWNKCLOYSRHCJ-BTTYYORXSA-N Granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 3
- 230000036740 Metabolism Effects 0.000 description 3
- 229940072273 Pepcid Drugs 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000002378 acidificating Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 201000008286 diarrhea Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000035786 metabolism Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006011 modification reaction Methods 0.000 description 3
- 230000001537 neural Effects 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- 230000001936 parietal Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000003248 secreting Effects 0.000 description 3
- 231100000486 side effect Toxicity 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissues Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 229960004373 Acetylcholine Drugs 0.000 description 2
- 229940072293 Axid Drugs 0.000 description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N Diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 2
- 210000002322 Enterochromaffin Cells Anatomy 0.000 description 2
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 2
- 108040006927 G protein-coupled serotonin receptor activity proteins Proteins 0.000 description 2
- 210000003736 Gastrointestinal Contents Anatomy 0.000 description 2
- 229960003727 Granisetron Drugs 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 210000000936 Intestines Anatomy 0.000 description 2
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 2
- 230000035633 Metabolized Effects 0.000 description 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N Metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 210000003205 Muscles Anatomy 0.000 description 2
- 229940032668 Prevacid Drugs 0.000 description 2
- GZSKEXSLDPEFPT-IINYFYTJSA-N Renzapride Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)N[C@H]1[C@H](C2)CCC[N@]2CC1 GZSKEXSLDPEFPT-IINYFYTJSA-N 0.000 description 2
- 229950003039 Renzapride Drugs 0.000 description 2
- QAZLUNIWYYOJPC-UHFFFAOYSA-M Sulfenamide Chemical compound [Cl-].COC1=C(C)C=[N+]2C3=NC4=CC=C(OC)C=C4N3SCC2=C1C QAZLUNIWYYOJPC-UHFFFAOYSA-M 0.000 description 2
- 229940106721 Tagamet Drugs 0.000 description 2
- 208000002363 Torsades de Pointes Diseases 0.000 description 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Tranquisan Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 2
- FEZBIKUBAYAZIU-UHFFFAOYSA-N Trimethobenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC=2C=CC(OCCN(C)C)=CC=2)=C1 FEZBIKUBAYAZIU-UHFFFAOYSA-N 0.000 description 2
- 208000003663 Ventricular Fibrillation Diseases 0.000 description 2
- FEROPKNOYKURCJ-UHFFFAOYSA-N Zacopride Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1C(CC2)CCN2C1 FEROPKNOYKURCJ-UHFFFAOYSA-N 0.000 description 2
- 229950004681 Zacopride Drugs 0.000 description 2
- 229940108322 Zantac Drugs 0.000 description 2
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 2
- FTFYNJYNMCKWAJ-JQOFMKNESA-F [(2R,3S,4S,5R)-2,4-bis($l^{1}-alumanyloxysulfonyloxy)-5-($l^{1}-alumanyloxysulfonyloxymethyl)-5-[(2S,3R,4S,5R,6R)-3,4,5-tris($l^{1}-alumanyloxysulfonyloxy)-6-($l^{1}-alumanyloxysulfonyloxymethyl)oxan-2-yl]oxyoxolan-3-yl]oxysulfonyloxyaluminum;hexadecahydr Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.[Al]OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al])[C@H](OS(=O)(=O)O[Al])[C@@H](COS(=O)(=O)O[Al])O[C@H]1O[C@@]1(COS(=O)(=O)O[Al])[C@@H](OS(=O)(=O)O[Al])[C@H](OS(=O)(=O)O[Al])[C@@H](OS(=O)(=O)O[Al])O1 FTFYNJYNMCKWAJ-JQOFMKNESA-F 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001556 benzimidazoles Chemical class 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- XAUTYMZTJWXZHZ-IGUOPLJTSA-K bismuth;(E)-1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 XAUTYMZTJWXZHZ-IGUOPLJTSA-K 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229960000520 diphenhydramine Drugs 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 229960004242 dronabinol Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 201000000052 gastrinoma Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 239000003979 granulating agent Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 201000005081 intestinal pseudo-obstruction Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000003902 lesions Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229960004503 metoclopramide Drugs 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000003000 nontoxic Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000000414 obstructive Effects 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 230000002335 preservative Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000000611 regression analysis Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000002195 synergetic Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 229960004161 trimethobenzamide Drugs 0.000 description 2
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 2
- 229960003688 tropisetron Drugs 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- OMLDMGPCWMBPAN-UHFFFAOYSA-N 4-amino-5-chloro-2-methoxy-N-(3-methoxypiperidin-4-yl)benzamide Chemical compound COC1CNCCC1NC(=O)C1=CC(Cl)=C(N)C=C1OC OMLDMGPCWMBPAN-UHFFFAOYSA-N 0.000 description 1
- DCSUBABJRXZOMT-RBBKRZOGSA-N 4-amino-5-chloro-N-[(3R,4S)-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-yl]-2-methoxybenzamide Chemical compound C([C@H]([C@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-RBBKRZOGSA-N 0.000 description 1
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 1
- 229930006677 A03BA01 - Atropine Natural products 0.000 description 1
- 230000035928 Absorption time Effects 0.000 description 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N Amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 229940071731 Antivert Drugs 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N Atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 Atropine Drugs 0.000 description 1
- 229940088007 Benadryl Drugs 0.000 description 1
- 229940054066 Benzamide antipsychotics Drugs 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 230000036868 Blood Concentration Effects 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- 229940027088 Carafate Drugs 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N Chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 Chloroprocaine Drugs 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 229940088505 Compazine Drugs 0.000 description 1
- 229940095074 Cyclic AMP Drugs 0.000 description 1
- 210000000172 Cytosol Anatomy 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- 206010013781 Dry mouth Diseases 0.000 description 1
- 210000000111 Esophageal Sphincter, Lower Anatomy 0.000 description 1
- 229940012017 Ethylenediamine Drugs 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102100001448 GAST Human genes 0.000 description 1
- 101700005903 GAST Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 206010019233 Headache Diseases 0.000 description 1
- 102000000543 Histamine receptors Human genes 0.000 description 1
- 108010002059 Histamine receptors Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N Hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 210000001153 Interneurons Anatomy 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N Ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229940099262 Marinol Drugs 0.000 description 1
- 229940041321 Meclizine Drugs 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor family Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor family Proteins 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 210000003249 Myenteric Plexus Anatomy 0.000 description 1
- 229940039506 Mylanta Drugs 0.000 description 1
- 210000000329 Myocytes, Smooth Muscle Anatomy 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N N',N'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- 210000001577 Neostriatum Anatomy 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 210000001914 Parietal Cells, Gastric Anatomy 0.000 description 1
- 229960000762 Perphenazine Drugs 0.000 description 1
- 229940107333 Phenergan Drugs 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229940068965 Polysorbates Drugs 0.000 description 1
- 229940089505 Prilosec Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N Prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229940080693 Reglan Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 229960004291 Sucralfate Drugs 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 229940033529 Tetrahydrocannabinol Drugs 0.000 description 1
- CFMYXEVWODSLAX-QOZOJKKESA-N Tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 1
- 229950010357 Tetrodotoxin Drugs 0.000 description 1
- 229940028300 Tigan Drugs 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 210000001186 Vagus Nerve Anatomy 0.000 description 1
- 206010065341 Ventricular tachyarrhythmia Diseases 0.000 description 1
- 206010047302 Ventricular tachycardia Diseases 0.000 description 1
- 229940072018 Zofran Drugs 0.000 description 1
- DDSZWBCJXDRQDU-UHFFFAOYSA-N [N].C1CCNCC1 Chemical compound [N].C1CCNCC1 DDSZWBCJXDRQDU-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000003187 abdominal Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003474 anti-emetic Effects 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 210000003882 argentaffin cell Anatomy 0.000 description 1
- 238000007262 aromatic hydroxylation reaction Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003542 behavioural Effects 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000002210 biocatalytic Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N cAMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Chemical class 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical class [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 230000011128 cardiac conduction Effects 0.000 description 1
- 230000003684 cardiac depression Effects 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 108091008012 chemoreceptors Proteins 0.000 description 1
- CRBHXDCYXIISFC-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CC[O-] CRBHXDCYXIISFC-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 238000006900 dealkylation reaction Methods 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 201000003066 diffuse scleroderma Diseases 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 201000003010 gallbladder disease Diseases 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 101700035385 lili Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical class [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Chemical class 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 230000002503 metabolic Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- KJBLQGHJOCAOJP-UHFFFAOYSA-N metoclopramide hydrochloride Chemical compound O.Cl.CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC KJBLQGHJOCAOJP-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000002569 neurons Anatomy 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 230000000422 nocturnal Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 230000002093 peripheral Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000007943 positive regulation of appetite Effects 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000003523 serotonin 4 antagonist Substances 0.000 description 1
- 239000000387 serotonin 5-HT4 receptor agonist Substances 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000707 stereoselective Effects 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- RVEZZJVBDQCTEF-UHFFFAOYSA-N sulfenic acid Chemical compound SO RVEZZJVBDQCTEF-UHFFFAOYSA-N 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid group Chemical class S(O)(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002889 sympathetic Effects 0.000 description 1
- 201000009594 systemic scleroderma Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- RVBRTNPNFYFDMZ-SPIKMXEPSA-N thiethylperazine maleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C12=CC(SCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 RVBRTNPNFYFDMZ-SPIKMXEPSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Chemical class 0.000 description 1
- 239000011701 zinc Chemical class 0.000 description 1
Abstract
The invention relates to methods and compositions for the prevention, treatment, or management of gastrointestinal disorders or symptoms thereof, employing two or more agents or compounds to provide a triple site action on 5-HT3 receptors, 5-HT4 receptors, and at least one of H2 receptors and proton pumps.
Description
METHODS AND COMPOSITIONS USING (+) NORCISAPRIDE IN COMBINATION WITH PROTON PUMP INHIBITORS OR RECEPTOR ANTAGONISTS FOR H2
1. FIELD OF THE INVENTION The invention relates to methods and compositions for the prevention, treatment or management of gastrointestinal disorders or symptoms of these, by the administration of one or more agent (s) compound (s) which at the same time or sequentially act on a receptor for 5-HT3, a receptor for 5-HT4 and a receptor for H2 or a proton pump.
2. BACKGROUND OF THE INVENTION Gastrointestinal disorders are common conditions that affect the gastrointestinal tract, that is, the stomach and intestines. There are some gastrointestinal disorders that include: gastro-esophageal reflux disease, emesis, gastrointestinal motility dysfunction, gastrointestinal ulcers, pathological conditions of hypersecretion and gastric hyperacidity. These diseases can be treated by different non-invasive means such as the administration to a patient of a therapeutic agent such as ZANTAC® (ranitidine), TRITEC® (ranitidine), AXID® (nizatidine), TAGAMET® (cimetidine), PREVACID® (lansoprazole) , PEPCID®, PEPCID
AC® ACID CONTROLLER®, MYLANTA AR ACID REDUCER ™
(famotidine), PRISOLEC® (omeprazole), and others.
New compounds and pharmaceutical preparations are continuously developed. U.S. Patent Nos. 4,962,115, 5,075,525 and 5,137,896 (collectively "Van Daele") describe N- (3-hydroxy-4-piperidenyl) benzamides [sic]. It is said that these compounds stimulate the motility of the gastrointestinal system. Van Daele states that the diastereomeric cis and trans racemates of these compounds can be obtained separately by traditional methods, and the diastereomeric cis and trans racemates can also be resolved in their optical isomers. Such a racemate, cisapride, has the chemical name cis-4-amino-5-chloro-N- [1- [3- (4-fluorophenoxy) propyl] -3-methoxy-4-piperidinyl] -2-methoxybenzamide. Schapira et al., Acta Gastroenterolog. Belg., Lili: 446-457 (1990). Cisapride is mainly used to treat gastroesophageal reflux disease ("GERD"), which is characterized as the backward flow of stomach contents into the esophagus. Cisapride is commercially available as the racemic mixture of the cis (-) and cis (+) diastereomeric enantiomers of cisapride known as PROPULSID®. The benzamide derivatives have some prominent pharmacological actions due to their effects on the neuronal systems modulated by the neurotransmitter serotonin. It has been reported that a major serotonin production and storage site is the enterochromaffin cell of the gastrointestinal mucosa. It was also reported that serotonin provides powerful intestinal transit and decreased absorption time, as ^^ 10 occurs with diarrhea. This stimulating action is also associated with nausea and vomiting. Due to its modulation of serotonin from the neuronal system in the gastrointestinal tract, some benzamide derivatives are effective antiemetic agents and are
used to control vomiting during cancer chemotherapy or radiation therapy. Costall et al., Neuropharmacology, 26: 1321-1326 (1987). This action is the result of an ability to block serotonin
• at specific sites, in particular the recipients for
5-hydroxytryptamine type 3 (5-HT3). Clarke et al., Trends in Pharmacological Sciences, 10: 385-386 (1989). Chemotherapy and radiation therapy can induce nausea and vomiting due to damage to enterochromaffin cells in the gastrointestinal tract. As a result, the
The neurotransmitter serotonin is released and stimulates the afferent fibers of the vagus nerve (thus initiating the vomiting reflex) and the serotonin receptors in
• the activation zone of chemoreceptors in the region of the postrema area of the brain. The anatomical site for this action of the benzamide derivatives remains unresolved, and if its action is central (SNC), peripheral or a combination of these. Barnes et al., J. Pharm. Pharmacol. , 40: 586-588 (1988). A second prominent action of certain benzamide derivatives is the increase in gastrointestinal smooth muscle activity from the esophagus to the proximal small intestine, thus accelerating esophageal and small bowel transit, as well as facilitating gastric emptying and increasing gastric emptying. the tone of the sphincter
lower esophageal. Decktor et al., Eur. J. Pharmacol. , 147: 313-316 (1988). Although the benzamide derivatives are not agonists of the cholinc receptors per se, the aforementioned effects on the smooth muscle can be blocked by the blocking agents of the
muscarinic receptors such as atropine or inhibitors of neuronal transmissions such as the tetrodotoxin type that blocks sodium channels. Fernandez and Massingham, Life Sci. , 36: 1-14 (1985). Similar blocking activity has been reported for the effects
contractile serotonin in the small intestine.
Craig and Clarke, Bri t J. Pharmacol. , 96: 247P (1989). It is believed that the main effects on smooth muscle of benzamide derivatives are the result of an agonist action on a class of serotonin receptors known as receptors for 5-HT4, which are located in the interneurons in the myenteric plexus of the wall intestinal. Clarke et al., Trends in Pharmacological Sciences, 10: 385-386 (1989) and Dumuis et al., N. S. Arch. Pharmacol. , 340: 403-410 (1989). The activation of these receptors subsequently improves the release of acetylcholine from the nerve terminals for sympathetics located near the surrounding smooth muscle fibers. The combination of acetylcholine with its receptors on the smooth muscle membranes is the real activator of muscle contraction. It has been reported that cisapride enters the central nervous system and binds to the receptors for 5-HT4. This indicates that cisapride can have mid-effects from the center. Cisapride is a potential ligand in receptors for 5-HT, which are located in some areas of the central nervous system. Dumuis et al., N. S. Arch Pharmacol. , 340: 403-410 (1989). The modulation of serotonc systems can have a variety of behavioral effects. The co-administration of racemic cisapride with other therapeutic agents causes problems of inhibition with the metabolism of cisapride by the liver. For example, him
• ketaconazole has a pronounced effect on the kinetics of cisapride resulting from the inhibition of the metabolic elimination of cisapride and gives rise to an 8-fold increase in plasma concentrations in the steady state. Physicians Desk Reference®, Medical Economics Co., Inc., p. 1308-1309, 52nd edition (1988). The interaction of racemic cisapride and other agents
Therapeutic agents can also potentiate cardiovascular side effects such as cardiotoxicity. This potentiation occurs when other drugs present in the patient's system interfere with the metabolism of cisapride, thus causing an accumulation of
racemic cisapride in the body. These interactions are a major disadvantage for the use of racemic cisapride; in particular, because racemic cisapride is usually used before, with or immediately after another therapeutic agent.
In addition, it has been found that the administration of racemic cisapride to a human causes adverse effects such as cardiac arrhythmia, including ventricular tachycardia, ventricular fibrillation, Qt prolongation and torsades de pointes, effects on the nervous system
Central nervous system ("CNS"), increase in systolic pressure, interactions with other medications, diarrhea, abdominal cramps, and cardiac depression. Racemic Cisapride in humans is metabolized primarily by N-oxidative dealkylation of piperidine nitrogen or by aromatic hydroxylation occurring on either the 4-fluorophenoxy or benzamide rings. Meuldermans et al., Drug Metab. Dispos , 16 (3): 410-419 (1988); and Meuldermans et al., Drug Metab. Dispos , 16 (3): 403-409 (1988). Norcisapride, with the chemical 4-amino-5-chloro-N- (3-methoxy-4-piperidinyl) -2-methoxybenzamide is an active metabolite of cisapride. Recently, researchers have reported that the optically pure stereoisomer (+) of the metabolite of cisapride, norcisaprida, presents multiple useful characteristics, but without certain side effects of racemic cisapride. Specifically, U.S. Patent No. 5,739,151 describes a method for elucidating an antiemetic effect and treating other conditions using (+) optically pure norcisapride. Other agents or compounds that have been studied for the treatment of gastrointestinal diseases include proton pump inhibitors and H2 receptor antagonists. Proton pump inhibitors treat gastrointestinal diseases by inhibiting H + -K + ATPase and thereby regulate acidity in gastric juices. H2-receptor antagonists inhibit the binding of histamine with H2 receptors to regulate the secretion of gastric acid. Goodman & Gilman, The Pharmacological Basis of Therapeutics, 9th edition, pp. 901-915 (1996). Concentration gradients of gastric acids across cell membranes vary widely. Perhaps the largest gradient in the body occurs through the plasma membrane of the parietal cells of the lining of the stomach, which secretes hydrochloric acid in the gastric juice. Since the concentration of hydrochloric acid in the gastric juice can be as high as 0.1 M and the concentration of H + in the cells is approximately 10 ~ 7 M, the parietal cells can secrete H + ions against a concentration gradient of approximately 1 million. a 1. A membrane-bound enzyme called H + -K + ATPase facilitates the active transport of H + through the membranes against concentration gradients in exchange for K + to form gastric hydrochloric acid. For each molecule of cytosolic ATP hydrolysed to ADP and phosphate, two H + ions are transported through the plasma membrane from the cytosol to the stomach. Goodman & Gilman, The Pharmacological Basis of Therapeutics, 9th edition, pp. 901-915 (1996).
• Proton pump inhibitors suppress the secretion of gastric acid, the final step of acid production, by the specific inhibition of the enzymatic system H + -K + ATPase on the secretory surface of gastric parietal cells. Proton pump inhibitors include benzimidazole compounds, for example, omeprazole (PRILOSEC®),
^^ 10 lanzoprazole (PREVACID®), and pantoprazole. These proton pump inhibitors contain a sulfinyl group located between the substituted benzimidazole and pyridine rings. At neutral pH, omeprazole, lansoprazole and pantoprazole are chemically stable weak bases,
soluble in lipids that are devoid of inhibitory activity. These weak bases without charge reach the parietal cells from the blood and spread to the secretory canaliculi, where the drugs are
• they protonate and by this means they are trapped. The species
protonates are rearranged to form a sulfenic acid and a sulfenamide, the last species capable of interacting with the sulfhydryl groups of H + -K + ATPase. Complete inhibition occurs with two inhibitor molecules per enzyme molecule. The specificity of
The effects of proton pump inhibitors, it is believed, come from: a) the selective distribution of H + -K + ATPase b) the requirement of acidic conditions
• to catalyze the generation of the reactive inhibitor; and c) trapping the protonated medicament and the cationic sulfenamide within the acidic canaliculi adjacent to the chosen enzyme. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th edition, pp. 901-915 (1996). Antagonists of H2 receptors inhibit
competitively interacting with histamine receptors for H2. These are highly selective and have little or no effect on the receivers for Hi. Although H2 receptors are present in numerous tissues, including vascular smooth muscle and
In contrast to bronchial, antagonists for H2 receptors interfere significantly with physiological functions other than gastric acid secretion. Antagonists of H2 receptors include nizatidine (AXID®), ranitidine (ZANTAC® and
TRITEC®), famotidine (PEPCID AC®), and cimetidine (TAGAMET®). Goodman & Gilman's The Pharmacological Basis of Therapeutics cs, 9th edition, pp. 901-915 (1996). H2-receptor antagonists inhibit the secretion of gastric acid elucidated by the
histamine, other agonists for H2, gastrin, and, to a lesser extent, muscarinic agonists. Antagonists of the receptors for H also inhibit base and nocturnal acid secretion, and this effect contributes in an important way to their clinical efficacy. 5 Although therapeutic agents are available, a more effective, broad spectrum treatment or treatment for gastrointestinal disorders is still necessary. For example, it is desirable to have safe and effective methods and compositions for the
^^ 10 prevention, treatment and management of gastrointestinal disorders without adverse effects or drug-medication interactions.
3. COMPENDIUM OF THE INVENTION The invention comprises the prevention, treatment or management of gastrointestinal disorders by biological action at three different sites: the action on the receptors for 5-HT3, the receptors for 5-HT and the
• receivers for H or proton pumps. Is considered
that the use of the triple action provides an unexpectedly superior therapeutic profile. The use of this triple action treatment may be less toxic and / or more potent for the prevention, treatment and management of gastrointestinal disorders compared to
use of agents that act only on any of the three sites. In one embodiment, three therapeutic agents or compounds are used, one providing action at the 5-HT3 receptors, another providing action at the 5-HT4 receptors and the third being a proton pump inhibitor or a receptor antagonist for H2. For example, in a preferred embodiment, cisapride, ondansetron and any proton pump inhibitor or a receptor antagonist for H is used to prevent, treat or manage gastrointestinal disorders. In a more preferred embodiment, optically pure (+) cisapride or
(-) optically pure cisapride, or a pharmaceutically acceptable salt thereof, optically pure R (+) ondansentron or a pharmaceutically acceptable salt thereof, and a proton pump inhibitor or a H2 receptor antagonist. In another embodiment, the invention comprises the synergistic use of two or more agents or compounds to provide triple action at the site on the 5-HT3 receptors, the 5-HT4 receptors and the H-receptors or the proton pumps. In a preferred embodiment, two agents or compounds are used, one providing double action at the receptors for 5-HT3 and the receptors for 5-HT4, and the other providing action at the receptors for H2 or proton pumps. For example, in this modality
• preferred (+) optically pure norcisapride, or one of its acceptable salts for pharmaceutical use, which have
activity 5-HT3 and 5-HT4, and a proton pump inhibitor or H2 receptor antagonist are used to prevent, treat or manage gastrointestinal disorders. ^^ This invention also comprises the use of two
^^ 10 separate pharmaceutical compositions adapted for the prevention, treatment or management of a patient suffering from gastrointestinal disorders or their symptoms, one of which comprises a therapeutically effective amount of optically pure (+) norcisapride or an acceptable salt
for pharmaceutical use thereof, and another with an effective amount for therapeutic use of a proton pump inhibitor or H2 receptor antagonist. Otherwise, the invention also comprises pharmaceutical compositions comprising optically pure 20 (+) norcisapride or a pharmaceutically acceptable salt thereof, in combination with a proton pump inhibitor or an H2 receptor antagonist. The individual unit dosage forms comprise from about 0.5 mg to about 500 mg of optically pure (+) norcisapride, or one of its pharmaceutically acceptable salts, and from about 1 mg to about 200 mg of a pump inhibitor. protons or from about 1 mg to about 2400 mg of an H2 receptor antagonist in a suitable vehicle. The pharmaceutical compositions and methods of the invention, particularly those comprising an effective amount for therapeutic use of optically pure (+) norcisapride or one of its pharmaceutically acceptable salts, can be used to prevent or alleviate symptoms of gastrointestinal disorders by reducing or avoiding at the same time adverse effects associated with the administration of traditional treatments such as 5-HT3 receptor antagonists, 5-HT receptor agonists or antagonists, H receptor antagonists and traditional proton pump inhibitors. In addition, the compositions and methods of the present invention comprise the treatment, prevention or management of gastrointestinal disorders by reducing or avoiding at the same time drug-drug adverse interactions that are known to occur with the use of existing commercial agents, such as cisapride. racemic
4. DETAILED DESCRIPTION OF THE INVENTION The invention comprises the prevention, treatment or management of gastrointestinal disorders by the biological action in three different sites, action on the receptors for 5-HT3, the receptors for 5-HT and the receptors for H2 or the pumps of protons (for example, the inhibition of the enzymatic system H + -K + ATPase). It is considered that the use of the triple action in the site provides a therapeutic profile unexpectedly superior to the traditional treatment of gastrointestinal disorders. The use of this triple action treatment may be safer and / or more effective for the prevention, treatment and management of gastrointestinal disorders than the use of agents that act only in one of the three sites. More specifically, the invention also comprises the use of at least three agents or compounds to prevent, treat or manage gastrointestinal disorders, or the symptoms thereof, one providing action at 5-HT3 receptors, another providing action at 5-HT receptors. and a third providing action in the systems of the proton pumps or the H2 receivers. Preferably, the three compounds are cisapride, ondasetron and a proton pump inhibitor or a H2 receptor antagonist. Most preferably, the three co-regimens are (+) optically pure cisapride or optically pure (-) cisapride, or one of its pharmaceutically acceptable salts, optically pure R (+) ondansetron or one of its pharmaceutically acceptable salts, and a proton pump inhibitor or a receptor antagonist for H2. The invention also comprises the use of synergist of at least two agents or compounds to provide triple action on the receptors for 5-HT3, the receptors for 5-HT4 and the receptors for H2 or the mechanism of the proton pump, in the prevention , treatment or management of gastrointestinal disorders. Preferably, two agents or compounds are used, one providing double action at the receptors for 5-HT3 and the receptors for 5-HT4, and the other providing action at the receptors for H2 or the proton pump systems. More preferably, the two agents or compounds are (+) optically pure norcisapride or one of its salts acceptable for pharmaceutical use, and a receptor antagonist for H2 or a proton pump inhibitor. Gastrointestinal disorders that can be treated by the compositions and methods of the invention include, but are not limited to, upper and lower gastrointestinal system disorders, gastroesophageal reflux disease ("GERD"), emesis, gastrointestinal motility dysfunction, ulcers. gastrointestinal, pathological states of hypersecretion and gastric hyperacidity. Gastrointestinal disorders also include, but are not limited to, dyspepsia, gastroparesis, constipation, postoperative ileus, pseudo intestinal obstruction, gastric ulcers, duodenal ulcers, heartburn, acid indigestion, erosive esophagitis, stomach acid, upset stomach, and Zollinger syndrome. -Ellisson. In a more preferred embodiment, the invention comprises the use of optically pure (+) norcisapride, or one of its pharmaceutically acceptable salts, and at least one proton pump inhibitor or one receptor antagonist for H, in the prevention, treatment or management of gastrointestinal disorders, or symptoms of these. It should be noted that racemic norcisapride, or one of its pharmaceutically acceptable salts, can be used as an alternative to (+) optically pure norcisapride in the methods and compositions of the invention, although (+) optically pure norcisapride is preferred. Similarly, optically pure stereoisomers or active metabolites of proton pump inhibitors or H2 antagonists can also be used as alternatives where appropriate, as well as acceptable salts for pharmaceutical use thereof. Specific examples only as an illustration are set forth below. Without adhering to the theory, it is considered that the use of an agent or compound having double activity as a receptor antagonist for 5-HT3 and an antagonist for 5-HT4 receptors together with a proton pump inhibitor or a H2-receptor antagonist provides triple action at the site, which surprisingly gives rise to clearer dose-related definitions in terms of efficacy, decrease in adverse affects, superior treatment due to synergistic activity and, consequently, a better therapeutic index. For example, (+) optically pure norcisapride has dual activity as an antagonist of 5-HT3 receptors and 5-HT4 receptor agonist, and triple action is achieved at the site when used with a proton pump inhibitor or a H2 receptor antagonist. Therefore, it is more desirable to use the compositions and methods of the invention than to use a 5-HT3 receptor antagonist, a 5-HT4 receptor agonist, an agent or compound having dual activity as a receptor antagonist. for 5-HT3 and a 5-HT4 receptor agonist, a proton pump inhibitor or a H2 receptor antagonist alone. 5 The use of optically pure (+) norcisapride or one of its acceptable salts for pharmaceutical use with a proton pump inhibitor or a H2 receptor antagonist, in the prevention, treatment or
^^ Management of gastrointestinal disorders, according to
The present invention is considered to reduce or avoid the adverse effects associated with existing treatment for gastrointestinal disorders such as racemic cisapride. In addition, it is considered that this modality reduces or avoids associated drug-drug adverse interactions
with racemic cisapride. The invention also includes the methods of prevention, treatment or management of a condition caused by a dysfunction of the 5-HT3 receptors,
• receptors for 5-HT4 or proton pumps or 20 H2 receptors by administering an effective amount for therapeutic use of optically pure (+) norcisapride or one of its acceptable salts for pharmaceutical use, with an effective amount for therapeutic use of a proton pump inhibitor or a H2 receptor antagonist.
The invention comprises the methods of prevention, treatment or management of GERD, emesis, gastrointestinal motility dysfunction, gastrointestinal ulcers, pathological conditions of hypersecretion or gastric hyperacidity, which consists of administering to a patient an effective amount for therapeutic use of (+) optically pure norcisapride, or one of its acceptable pharmaceutically acceptable salts, with a proton pump inhibitor or a H2 receptor antagonist. In specific embodiments, the invention also comprises the use of these agents in combination for the prevention, treatment or management of erosive esophagitis, dyspepsia, gastroparesis, constipation, postoperative ileus, intestinal pseudo-obstruction, gastric ulcers, duodenal ulcers, heartburn, indigestion acid, erosive esophagitis [sic], heartburn, upset stomach and Zollinger-Ellison syndrome. The invention, which comprises the use of triple action treatment, may optionally further include the use of one or more additional therapeutic agents known to treat gastrointestinal disorders. Examples of additional therapeutic agents include, but are not limited to, hydroxyzine (ANTARAX®); diphenhydramine (BENADRYL PARENTAREL®); perchloroperazine (COMPAZINE®); dronabinol (MARINOL®); proraetazine (PHENERGAN®);
meclizine (ANTIVERT®); trimethobenzamide (TIGAN®); tietilperazine (TORECAN®); perphenazine (TRILAFON®); sucralfate (CARAFATE®); and the like, and as applicable, the optically pure stereoisomers or the active metabolites thereof. The administration of two or more therapeutic agents used according to the methods of the invention may be concurrent, sequential or both, i.e.
^^ (+) optically pure norcisapride, or one of its salts
Acceptable pharmaceutical use, and a proton pump inhibitor or a H2 receptor antagonist, and optionally an additional therapeutic agent, can be administered as a combination, concurrently but separately or by sequential administration. It is considered that the methods and compositions of this invention provide the benefit of reducing or avoiding the adverse effects associated with the above methods and the compositions used in the treatment of
• gastrointestinal disorders. See, for example,
Physician's Desk Reference®, Medical Economics Co., Inc., 52nd edition (1998 and 1999). The terms "adverse effects" and "adverse side effects", when used herein, include, but are not limited to, cardiac arrhythmia,
disorders of cardiac conduction, appetite stimulation, weight gain, sedation, gastrointestinal discomfort, headache, dry mouth, constipation, diarrhea and drug-medication interactions. The term "cardiac arrhythmia" includes, but is not limited to, ventricular tachyarrhythmia, torsades de pointes, Qt prolongation, and ventricular fibrillation. The term "gastrointestinal disorder," when used herein, includes but is not limited to, gastrointestinal motility dysfunction., GERD, emesis, gastrointestinal ulcers, pathological states of hypersecretion, gastric hyperacidity, erosive esophagitis, dyspepsia, gastroparesis, constipation, postoperative ileus, intestinal pseudo-obstruction, gastric ulcers, duodenal ulcers, heartburn, acid indigestion, erosive esophagitis, acidity stomach, upset stomach and Zollinger-Ellison syndrome. The term "patient" when used herein refers to a mammal, in particular a human. The term "racemic", when used herein, is defined as a mixture of the (+) and (-) enantiomers of a compound, wherein the (+) and (-) enantiomers are present in a ratio of about 1: 1 The phrase "optically pure" when used herein means that the composition contains more than about 90% by weight of the desired stereoisomer,
• preferably more than about 95% by weight of the desired stereoisomer and, more preferably, more than about 99% by weight of the desired stereoisomer, based on the total weight of the active ingredient, for example, norcisapride when used to qualify (+) norcisapride. The term "practically free", when used in the present, means that less than
about 10% by weight, preferably less than about 5% by weight and more preferably less than about 1% by weight of the unwanted stereoisomer, for example, (-) norcisapride, is present according to the invention. The phrase "5-HT3 receptor antagonist," when used herein means a compound capable of reversibly binding to a receptor for 5-hydroxytryptamine type 3. Receptor antagonists for 5-HT3 include, but they are not limited to,
Granisetron (KYTRIL®), metoclopramide (REGLAN®), ondansetron (ZOFRAN®), renzapride, zacopride, tropisetron and, where appropriate, the optically pure stereoisomers or their active metabolites. The phrase "receptor agonist for 5-HT4",
when used herein means a compound capable of reversibly binding to a receptor for 5-hydroxytryptamine type 4. The agonists of the
• receptors for 5-HT4 include, but are not limited to, norcisapride and cisapride, and where appropriate, the 5 optically pure stereoisomers or active metabolites thereof. The phrase "proton pump" when used herein refers to H + -K + ATPase, an enzyme attached to the membrane that facilitates the active transport of H + through membranes against a concentration gradient. The phrase "proton pump inhibitor", when used herein, refers to any agent or compound that inhibits or suppresses the secretion of gastric acid by inhibiting the enzymatic system 15 H + -K + ATPase on the secretory surface of the gastric apyletal cells. Proton pump inhibitors include, but are not limited to, prazol derivatives such as omeprazole, lanzoprazole, pantoprazole,
• rabeprazole, and as applicable, optically pure stereoisomers such as (+) optically pure lanzoprazole, (-) optically pure lanzoprazole, (+) optically pure omeprazole, (-) optically pure omeprazole, (+) optically pure rabeprazole, () -) optically pure rabeprazole, (+) optically pure pantoprazole and (-) optically pure pantropazole, or the active metabolites thereof. The active metabolites of proton pump inhibitors suitable for use in accordance with the
• invention include, but are not limited to, hydroxy-omeprazole, hydroxy-lazoprazole, the carboxylic acid derivative of omeprazole and desmethyl-pantropazole, and as applicable, the optically pure stereoisomers thereof. Omeprazole, lanzoprazole, pantoprazole and rabeprazole, for example, can be prepared by the syntheses known to those skilled in the art,
of US Patent Nos. 4,544,750, 4,620,008, 4,620,008 [sic], 4,758,579, 5,045,552, 5,374,730, 5,386,032, 5,470,983 and 5,502,195, the descriptions of which are incorporated herein by express reference thereto. The phrase "H2 receptor antagonist" when used herein refers to any agent or compound that competitively inhibits the interaction of histamine with H2 receptors. Antagonists of H2 receptors include, but not
are limited to, cimetidine, famotidine, ranitidine, nizatidine and, where appropriate, optically pure stereoisomers or their active metabolites. The active metabolites of the H2 receptor antagonists include, but are not limited to, N2-25 monodesmethylnizatidine and, where appropriate, the optically pure stereoisomers thereof. Nizatidine can be prepared by synthesis
• known to those skilled in the art, particularly from U.S. Patent Nos. 5,541,335 and 5 5,700,945, the descriptions of which are each incorporated herein by express reference thereto. Ranitidine can be prepared by the synthesis known to those skilled in the art, particularly from U.S. Patent No. 5,118,813,
description of which is incorporated herein by express reference to this. Cimetidine can be prepared by the synthesis known to those skilled in the art, particularly from U.S. Patent Nos. 4,413,129, 4,855,439, 4,886,910,
4,886,912 and 5,118,813, the descriptions of which are each incorporated herein by reference. In addition, famotidine can be prepared by the synthesis known to those skilled in the art, described in, for example, Guimaraens et al., With tact Derma ti tis, 31
(4): 259 (1994). The diseases that can be prevented, treated or handled in the invention are used in the present in a consistent manner according to Stedman's Medical Dictionary, 26th edition Williams and Wilkins (1995). The terms "gastroesophageal reflux disease" or "GERD" when used herein is defined as a state characterized by backward flow of stomach contents into the esophagus. The term "gastrointestinal ulcer" when used herein is defined as a condition characterized by a lesion or lesions on the surface of the lining of the gastrointestinal tract, caused by superficial loss of tissue, usually accompanied by inflammation. Gastrointestinal ulcers include, but are not limited to, duodenal ulcers and gastric ulcers. The phrase "erosive esophagitis" when used herein is defined as a condition characterized by inflammation of the lower esophagus by refluxing the acid gastric contents, usually due to malfunction of the lower esophageal sphincter. The term "dyspepsia" when used herein, is defined as a state characterized by a deterioration in the strength or function of digestion that may arise as a symptom of primary gastrointestinal dysfunction or as a complication due to other disorders, such as appendicitis, gallbladder disorders or malnutrition. The term "gastroparesis" when used herein is defined as a stomach paralysis caused by motor abnormality in the stomach or as a complication of diseases such as diabetes, progressive systemic sclerosis, anorexia nervosa or myotonic dystrophy. The term "constipation" when used in the present is defined as a state characterized by infrequent or difficult stool evacuation resulting from conditions such as lack of intestinal muscle tone or intestinal spasticity. The phrase "postoperative ileus", when used herein is defined as an obstruction in the intestine due to disruption in muscle tone after surgery. The terms "prevent" and "prevention" when used herein are respectively defined as interrupting or preventing and the act of interrupting or preventing states or disorders in a patient who is at risk of suffering from such conditions or conditions including, but They are not limited to, patients suffering from stress. The phrase "pseudo intestinal obstruction" when used herein is defined as a condition characterized by constipation, colic pain and vomiting, but without evidence of physical obstruction. The phrase "gastric hyperacidity", when used herein is defined as a state characterized by an abnormally high degree of acidity in gastric juices. The phrase "effective amount for therapeutic use", when used herein is defined as the amount of a therapeutic agent that alone or in combination with other drugs provides a therapeutic benefit in the prevention, treatment or management of gastrointestinal disorders, but not limited to, gastrointestinal motility dysfunction, GERD, emesis, gastrointestinal ulcers, pathological hypersecretion states, gastric hyperacidity or symptoms of these. It is possible to apply each disorder to different effective therapeutic amounts, as is well known to those skilled in the art. The optically pure (+) norcisapride can be obtained from a racemic mixture of cisapride, the chemical synthesis of which can be carried out according to the method described in the application of European Patent No. 0,076,530 A2 published on April 13, 1983, or U.S. Patents 4,962,115, 5,057,525 or 5,137,896, the descriptions of which are each incorporated herein by express reference thereto. See also, Van Daele, et al., Drug Development Res., 8: 225-232 (1986). The metabolism of cisapride to norcisapride is described in Meuldermans, W., et al., Drug Metab. Dispos., 16 (3): 410-419 (1988); Y
Meuldermans et al., Drug Metab. Dispos., 16 (3): 403-409
(1988). The preparation of racemic norcisapride is also known to those skilled in the art,
particularly in view of EP 0,076,530 A2 and the Patent
No. 5,137,896 to Van Daele, the descriptions of which are incorporated herein by express reference thereto. The steroisomers
^^ optically pure of the chiral compounds described in
The present can also be obtained from the racemic mixture by resolution of the enantiomers using traditional means, for example, from an optically active acid that can be resolved. The resolution of racemic compounds
is also known to those skilled in the art, in particular from Jacques, J., et al., Enan tiomers, Racema tes and Resolutions, Wiley-Interscience, New York (1981);
Wilen, S. H. et al., Tetrahedron, 33: 2725 (1977); Eliel,
E. L. Stereochemistry of Coal Compounds, McGraw-Hill,
NY, (1962); Wilen, S. H. Tables of Resolving Agen ts and
Optical Resolutions, E. L. Elile, Ed., Univ. Of Notre
Dame Press, Notre Dame, IN, p. 268 (1972). In addition to the separation techniques, such as those described above, the compounds optically
Pure can be synthesized by stereospecific synthesis using methods well known to those skilled in the art. The chiral synthesis can
• give rise to products of high enantiomeric purity. However, in some cases, the enantiomeric purity of the product is not high enough. The skilled person will appreciate that the separation methods described in the above can be used to further improve the enantiomeric purity of the active stereoisomers that are obtained by chiral synthesis. For example, (+) optically pure norcisapride can also be prepared from the mixture of racemic norcisapride by enzymatic biocatalytic resolution. This synthesis is known to those skilled in the art, particularly of patents
US Nos. 5,057,427 and 5,077,217, the descriptions of which are incorporated herein by express reference thereto. The magnitude of a prophylactic or therapeutic dose of the active ingredients described herein, by
For example, (+) norcisapride, a 5-HT3 antagonist, a 5-HT4 agonist or antagonist, a proton pump inhibitor or a H2 receptor antagonist, in the acute or chronic management of disorders and diseases described herein, will vary with the
nature and severity of the state that is to be prevented, treated or managed and the route of administration. For example, it is possible to use oral, mucosal (including
• rectal), parenteral (including subcutaneous, intramuscular, bolus and intravenous), sublingual, transdermal, nasal, buccal and the like. Dosage forms include tablets, dragees, troches, lozenges, dispersions, suspensions, suppositories, solutions, capsules, soft elastic gelatin capsules, patches and the like. The dose, and maybe
the frequency of the dose will also vary according to the age, body weight and response of the individual patient. Convenient dosage schemes can be easily selected by those skilled in the art taking these factors into account. 15 In general, the total daily dose of 5-HT3 receptor antagonists, a 5-HT receptor agonist or a therapeutic agent that provides double action at 5-HT3 receptors and 5-HT4 receptors for the states described in
The present is from about 0.5 mg to about 500 mg, preferably from about 1 mg to about 350 mg, and most preferably from about 2 mg to about 250. The ranges of convenient daily doses can be easily determined by the experts in the art. In general, the total daily dose of a proton pump inhibitor for the presently described conditions, such as lansoprazole, pantoprazole, rabeprezole, omeprazole, or the optically pure stereoisomers or active metabolites thereof, is from about 1 mg to about 200 mg , preferably from about 5 mg to about 150 mg, and more preferably from about 10 mg to about 100 mg. In addition, those skilled in the art can easily determine the ranges of convenient daily doses of the H2 receptor antagonists. For example, see Physi cians Desk Reference® Medical Economics Co., Inc., 52nd edition (1999) for the convenient doses currently used for known H2 receptor antagonists. For example, ranitidine can be administered using an oral daily dose range of from about 1 mg to about 800 mg, preferably from about 100 mg to about 600 mg, and most preferably from about 250 mg to about 500 mg. For cimetidine, the range of the oral daily dose may be from about 1 mg to about 2400 mg, preferably from about 400 mg to about 1600 mg, more preferably from about 600 mg to about 1000 mg. For famotidine, the range of the oral daily dose may be from about 1 mg to about 200 mg, preferably from about 10 mg to about 80 mg, more preferably from about 15 mg to about 500 mg. For nizatidine, the range of the oral daily dose may be from about 1 mg to about 600 mg, preferably from about 50 mg to about 500 mg, more preferably from about 250 mg to about 350 mg. In the management of the patient, treatment can be initiated at a lower dose, for example, from about 0.5 mg to about 10 mg of
(+) norcisapride and from about 1 mg to about 5 mg of a proton pump inhibitor, or from about 1 mg to about 5 mg of a H2 receptor antagonist, and increasing to the recommended daily dose or higher depending on of the patient's overall response. Furthermore, it is recommended that children, patients over 65 years of age and those with impaired renal or hepatic function, receive low doses initially, and that these be titrated based on the individual response (s) and blood concentrations. It may be necessary to use dosages of each active ingredient outside the ranges herein described in some cases, as will be apparent to those skilled in the art. In addition, it should be indicated that the treating physician or clinician will know how and when to interrupt, adjust or terminate the treatment in relation to the patient's individual response. The pharmaceutical compositions for use in the present invention may comprise a 5-HT3 receptor antagonist and 5-HT4 receptor agonist, or a therapeutic agent that provides double action at 5-HT3 receptors and 5-HT3 receptors. -HT4 with a proton pump inhibitor or a H2 receptor antagonist as the active ingredients, and in addition may contain an acceptable carrier for pharmaceutical use and, optionally, other therapeutic ingredients. In one embodiment, the pharmaceutical compositions comprise three therapeutic agents, a 5-HT3 receptor antagonist and a 5-HT4 receptor agonist with a proton pump inhibitor or an H2 receptor antagonist, and in addition it can contain an acceptable carrier for pharmaceutical use and, optically pure, other therapeutic ingredients. In a preferred embodiment, the pharmaceutical compositions comprise two therapeutic agents, one providing double action at the receptors for 5-HT3 and the 5-HT4 receptors, and the other being a proton pump inhibitor or a receptor antagonist for H2. When used herein the term "pharmaceutically acceptable salt" refers to a salt prepared from non-toxic acids acceptable for pharmaceutical use including, but not limited to, inorganic acids, organic acids, solvates, hydrates. or clathrates of these. Examples of these inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric and phosphoric acids. Suitable organic acids can be selected, for example, from the classes of organic acids aliphatic, aromatic, carboxylic and sulphonic, examples of which are formic, acetic, propionic, succinic, benzoic, camphorsulfonic, citric, fumaric, gluconic, isethionic, lactic, malic, mucic, tartaric, para-toluenesulfonic, glycolic, glucuronic, maleic, furobic, glutamic, benzoic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamico), mentansulfonic, ethanesulfonic, pantothenic, benzenesulfonic, stearic, sulphanilic , alginic, galacturonic and the like. Particularly preferred acids are hydrochloric, phosphoric and sulfuric acids. In one embodiment, a 5-HT3 receptor antagonist, a 5-HT4 receptor agonist or a therapeutic agent providing double action as a 5-HT3 receptor antagonist and a 5-HT4 receptor agonist they are administered as free base or hydrate. For example, optically pure (+) norcisapride is administered as a free base or hydrate. The invention also contemplates the use of active agents or compounds which are acidic, in which it is possible to prepare the salts from non-toxic bases acceptable for pharmaceutical use including organic, inorganic bases, solvates, hydrates or clathrates thereof. Such inorganic bases include, but are not limited to, metal salts of aluminum, calcium, lithium, magnesium, potassium, sodium and zinc. Suitable organic bases include, but are not limited to, N, N-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylene diamine meglumain (N-methylglucamine), lysine and procaine. In practical use, the active agents in the pharmaceutical compositions of the invention can be combined as the active ingredients in intimate admixture with an acceptable carrier for pharmaceutical use of
• agreement with traditional pharmaceutical composition techniques. The carrier can take a wide variety of forms and comprises a number of components depending on the form of preparation desired for administration. The compositions of the present invention include, but are not limited to, suspensions, solutions and elixirs; aerosol sprays; or excipients that
includes, but is not limited to, starches, sugars, microcrystalline cellulose, diluents, granulating agents, binding lubricants, disintegrating agents and the like. Preferably, the pharmaceutical composition is in the form of a
oral preparation. Due to their ease of administration, tablets and capsules are preferred and represent the most advantageous oral dosage unit form, in which case excipients are used.
• solid pharmaceuticals. If desired, tablets may
be coated by normal aqueous or non-aqueous techniques. Preferably, the oral pharmaceutical compositions of the present invention can be administered in single or divided doses, from 1 to 4 times at
day Oral dosage forms can be conveniently presented in unit dosage forms and prepared by the well-known methods in
• the pharmacy technique. The pharmaceutical compositions herein
invention, suitable for oral administration, can be present as small dosage unit dosage forms, such as capsules, dragees, soft elastic gelatin capsules, tablets, or sprays
^^ in spray, each containing a quantity
The active ingredients, such as powder or granules, or as a solution or suspension in aqueous liquid, non-aqueous liquid, an oil-in-water emulsion or a water-in-oil liquid emulsion, are predetermined. Such compositions can be prepared by either of the methods well
known in the art of pharmacy, but all methods include the step of associating one or more active ingredients (s) with the carrier. In general, the compositions are prepared by uniformly and intimately mixing the active ingredients with the
liquid carriers or finely divided solid carriers, or both, and then, if necessary, shape the product into the desired presentation. Oral solid preparations are preferred over oral liquid preparations. A preferred oral solid preparation
are the capsules, but the most preferred oral solid preparation are the tablets. For example, it is possible to prepare a tablet by compression or molding, optionally, with one or more accessory ingredients. Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free-flowing form, such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, granulating agent, surface activating or dispersing agent, or Similary. The molded tablets can be prepared by molding, in a convenient machine, a mixture of the powdered compound moistened with an inert liquid diluent. Preferably, each tablet, dragee, capsule contains from about 0.5 mg to 500 mg of optically pure (+) norcisapride, more preferably from about 1 mg to about 350 mg, in combination with from about 1 mg to about 200 mg of a proton pump inhibitor or from about 1 mg to about 2400 mg of a H2 receptor antagonist. The pharmaceutical compositions of the present invention, suitable for oral administration, can be formulated as a pharmaceutical composition in a unit dosage form soft elastic gelatin capsule using traditional methods well known in the art, see, for example, Ebert, Pharm. Tech. 1 (5): 44-50 (1997). Soft elastic gelatin capsules have a soft gelatin shell, globular somewhat thicker than that of hard gelatin capsules, wherein a gelatin is plasticized by the addition of a plasticizing agent, for example, glycerin, sorbitol or a similar polyol. The hardness of the capsule shell can be changed by varying the type of gelatin used and the amounts of plasticizer and water. The soft gelatin covers may contain a preservative, such as methyl- and propylparabens and sorbic acid, to prevent the growth of fungi. The active ingredient can be dissolved or suspended in a liquid vehicle or carrier, such as vegetable or mineral oils, glycols such as polyethylene glycol and propylene glycol, triglycerides, surfactants such as polysorbates or a combination thereof. In addition to the common dosage forms set forth above, the compounds of the present invention may also be administered by controlled release delivery means or devices that are well known to those skilled in the art, such as those described in US Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; and 4,008,719, 5,674,533, 5,059,595, 5,591,767, 5,120,548,
• 5,073,543, 5,639,476, 5,354,556 and 5,733,566, the descriptions of which are each incorporated in the present by express reference to these. These pharmaceutical compositions can be used to provide slow or controlled release of one or more of the active ingredients using, for example, hydroxypropyl methylcellulose, other polymer matrices,
gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres or the like, or a combination thereof to provide the desired release profile in different proportions. The formulations for
Controlled, convenient release known to those skilled in the art, including those described herein, can be readily selected for use with the pharmaceutical compositions of the invention. Thus, the individual unit dosage forms
Suitable for oral administration, such as tablets, capsules, soft gelatin capsules, dragees and the like, which are adapted for controlled release are encompassed by the present invention. All pharmaceutical release products
controlled have a common goal of improving pharmacotherapy over that obtained by their non-controlled counterparts. In theory, the use of a controlled release preparation with optimized design in medical treatment is characterized by a minimum of the medicinal substance used to cure or control the condition in a minimum amount of time. The advantages of controlled release formulations may include: 1) prolonged activity of the medicament; ^^ 2) reduced frequency of dosing; and 3) greater
compliance of the patient. Most controlled release formulations are designed to initially release a quantity of the drug that immediately produces the desired therapeutic effect, and gradually and continuously
release other amounts of medication to maintain this level of therapeutic effect for a long time. To maintain this constant concentration of the drug in the body, the medication must be
• released from the dosage form at a rate that
will replace the amount of medication that is metabolized and excreted from the body. The controlled release of an active ingredient can be stimulated by different inducers, for example, pH, temperature, enzymes, water or other
states or physiological compounds. The term "controlled release component" in the context of the present invention is defined herein as a compound or compounds that includes, but is not limited to, polymers, polymer matrices, gels, permeable membranes, liposomes, microspheres or the like, or a combination thereof, which facilitates the controlled release of the active ingredient. The pharmaceutical compositions of the present invention can also be formulated for parenteral administration by injection (subcutaneous, bolus, intramuscular or intravenous injection) and can be dispensed in a unit dosage form, such as a multi-dose container or ampoule. Such compositions for parenteral administration may be in the form of suspensions, solutions, emulsions or the like in aqueous or oily vehicles and, in addition to the active ingredients may contain one or more form agents such as dispersing agents, suspending agents, stabilizing agents, preservatives and the like. Another route of administration is transdermal delivery, for example, by means of an abdominal skin patch. The invention is further defined by reference to the following examples which describe in detail the preparation of the compound and the compositions of the present invention, as well as its utility. It will be evident
• for those skilled in the art it is possible to make modifications to both materials and methods 5 without departing from the purpose and interest of this invention.
. EXAMPLES
^^ 5.1 EXAMPLE 1: Receptor binding 10 Receptor for 5-HT3 Racemic norcisapride, racemic cisapride and its stereoisomers (+) and (-) (Cerep, Celle l'Evescault, France) were tested for binding to the subtypes of the receptors for 5-HT3 from N1E-115 cells. After incubation with the appropriate ligands, the preparations were rapidly filtered in vacuo through GF / B glass fiber filters and washed with ice-cold buffer using a Brandel or Packard cell harvester. The determination of
radioactivity bound with a liquid scintillation counter (LS 6000, Beckman) using a liquid scintillation cocktail (Formula 989). The binding of the specific radio ligand to the receptor was defined as the difference between the total binding and the
non-specific binding determined in the presence of an excess of unlabeled ligand. The results were expressed as a percentage of the inhibition of the specific binding obtained in the presence of the compounds. The IC50 was determined using concentrations in the range from 3 x 10 ~ 10 M to 10 ~ 5 M to obtain complete competition curves and were calculated by non-linear regression analysis. The results are shown in Tables 3 and 4 below. Using the methods described above it is possible to test other active ingredients such as granisetron, metoclopramide, ondansetron, renzapride, zacopride, tropisetron and others.
Receptors for 5-HT4 Racemic norcisapride, racemic cisapride and its stereoisomers (+) and (-) (Cerep, Celle l'Evescault, France) were tested for binding to the 5-HT receptor subtypes from the striatum bodies. of guinea pig. After incubation with the appropriate ligands, the preparations were rapidly filtered in vacuo through GF / B glass fiber filters and washed with ice-cold buffer using a Brandel or Packard cell harvester. The unit radioactivity was determined with a liquid scintillation counter (LS 6000, Beckman) using a liquid scintillation cocktail (Formula 989). The binding of the radio ligand specific to the receptor was defined as the difference between the total binding and the non-specific binding determined in the presence of an excess of unlabeled ligand. The results were expressed as a percentage of the inhibition of the specific binding obtained in the presence of the compounds.
The IC5o was determined using concentrations in the range from 3 x 10"10 M to 10" 5 M to obtain complete competition curves and were calculated by non-linear regression analysis. The results are shown in Tables 3 and 4 below. Using the methods described above it is possible to test other active ingredients such as cisapride and the like.
TABLE 3 IC50 Values (nM) for binding to the 5-HT3 and 5-HT4 sites
TABLE 4 • IC50 values (nM) for binding to the 5-HT3 and 5-HT4 sites
The agonist activity in the sites of the
• 10 receptors for 5-HT4 can also be evaluated using an assay based on the ability of the active compounds to increase the production of cyclic AMP in mouse embryonic neurons grown in tissue culture (see Dumuis et al., N. S. Arch. 15 Pharma col., 340: 403-410 (1989)).
. 2 EXAMPLE 2: Oral formulation
• Tablets
Formula Quantity per tablet in mg
Active ingredients: A B C (+) norcisapride 5.0 10.0 25.0 Lansoprazole 5.0 15.0 30.0 Lactose BP 57.0 92.0 107.0 Starch BP 20.0 20.0 25.0 Microcrystalline cellulose 10.0 10.0 10.0 Hydrogenated vegetable oil 1.5 1.5 1.5 Polyvinylpyrrolidone 1.5 1.5 1.5 Compression weight 100.0 150.0 200.0
The active ingredients, (+) norcisapride and lansoprazole, are sieved through a convenient mesh and mixed with the lactose until a uniform mixture is formed. Suitable water volumes are added
and the powders are granulated. After drying, the granules are then sieved and mixed with the remaining excipients. The resulting granules are then compressed into tablets of desired shape. It is possible to prepare tablets in other concentrations by modifying the
ratio of the active ingredient to the excipient (s) or the compression weight.
. 3 EXAMPLE 3: Oral formulation
• Tablets
Formula Quantity per tablet in mg
Active ingredients: A B C (+) norcisapride 5.0 10.0 25.0 Famotidine 10.0 20.0 40.0 Lactose BP 38.5 73.5 43.5 Starch BP 30.0 30.0 60.0 Corn starch 15.0 15.0 30.0 Pregelatinized BP Magnesium stearate BP 1.5 1.5 1.5 Compression weight 100.0 150.0 540.0
The active ingredients (+) norcisapride and famotidine are screened through a suitable mesh and mixed with lactose, starch and pregelatinized corn starch until a uniform mixture is formed.
The suitable volumes of water are added and the powders are granulated. After drying, then the granules are sieved and mixed with the remaining excipients. The resulting granules are then compressed into tablets of the desired shape. It is possible to prepare
tablets of other concentrations modifying the ratio of the active ingredient to the excipient (s) or the weight of the compression.
. 4 EXAMPLE 4: Oral formulation
Tablets
Formula Quantity per tablet in mg
Active ingredient: A B C (+) norcisapride 5.0 10.0 25.0 Lactose BP 48.5 43.5 78.5 Starch BP 30.0 30.0 30.0 Corn starch 15.0 15.0 15.0
• pregelatinized BP Magnesium stearate BP 1.5 1.5 1.5 Compression weight 100.0 100.0 150.0
The active ingredient, (+) norcisapride, is sieved through a convenient mesh and mixed with lactose, starch and pregelatinized corn starch until a uniform mixture is formed. It adds the
convenient volumes of water and powder is granulated. B After drying, then the granules are sieved and mixed with the remaining excipients. Then the resulting granules are compressed into tablets of desired shape. It is possible to prepare tablets of other concentrations
modifying the ratio of the active ingredient to the excipient (s) or the compression weight. Although the present invention has been described with respect to the specific embodiments, it will be apparent to those skilled in the art that it is possible to make various changes and modifications without departing from the spirit and scope of the invention as defined in the clauses. Such modifications are also proposed to be within the scope of the attached clauses.
Claims (56)
1. A method of treating gastrointestinal disorders in a patient, which consists of 5 administering an effective therapeutic amount of one or more agent (s) or compound (s) acting simultaneously or sequentially on the 5-HT3 receptors, the 5-HT4 receptors and the proton pumps or ^^ receptors for H2, or an optically pure stereoisomer 10 or metabolite thereof, or one of its acceptable pharmaceutical salts.
2. A method for treating gastrointestinal disorders in a patient which consists of 15 administering an effective therapeutic amount of an agent or compound that antagonizes the 5-HT3 receptors and agonizes with the 5-HT4 receptors, and an effective therapeutic amount of at least one of the following: • a proton pump inhibitor or an antagonist 20 the receptors for H2, or an optically pure stereoisomer or active metabolite thereof, or one of its acceptable pharmaceutical salts.
3. A method for treating gastrointestinal disorders in a patient, which consists in administering to the patient an effective therapeutic amount of (+) norcisapride, or one of its acceptable pharmaceutical salts, practically without its stereoisomer (-), and a therapeutically effective amount of at least one proton pump inhibitor, one antagonist of the receptors for H2 or an optically pure stereoisomer or a metabolite thereof, or one of its acceptable pharmaceutical salts.
4. The method of claim 3, wherein the patient is a human.
5. The method of claim 3, wherein the gastrointestinal disorder is gastrointestinal motility dysfunction.
6. The method of claim 5, wherein the dysfunction of gastrointestinal motility is selected from the group consisting of dyspepsia, gastroparesis, constipation, postoperative ileus and pseudo intestinal obstruction.
7. The method of claim 3, wherein the gastrointestinal disorder is gastroesophageal reflux disease, emesis, gastrointestinal ulcers, pathological state of hypersecretion and gastric hyperacidity.
8. The method of claim 7, wherein the pathological state of hypersecretion is the syndrome of Zollinger-Ellison.
9. The method of claim 7, wherein the gastric hyperacidity is selected from the group consisting of heartburn, acid indigestion, stomach acidity, erosive esophagitis and upset stomach.
10. The method of claim 3, wherein the amount of (+) norcisapride administered is from about 0.5 rag to about 500 mg.
11. The method of claim 10, wherein the amount of (+) norcisapride that is administered is from about 1 mg to about 350 mg.
12. The method of claim 3 wherein the proton pump inhibitor is administered and is selected from the group consisting of omeprazole, lansoprazole, rabeprazole, pantoprazole, hydroxy-omeprazole, desmethyl-pantoprazole, hydroxylansoprazole, and an optically pure stereoisomer of these.
13. The method of claim 12, wherein the amount of the proton pump inhibitor is from 5 about 1 mg to about 200 mg.
14. The method of claim 13, wherein the amount of the proton pump inhibitor is from about 5 mg to about 150 mg. 15. The method of claim 3, wherein the H2 receptor antagonist is administered and is selected from the group consisting of cimetidine, ranitidine, famotidine, nizatidine, or a stereoisomer
15 optically pure or an active metabolite of these.
16. The method of claim 15, wherein the amount of the H2 receptor antagonist is from about 1 mg to about 2400 mg.
17. The method of claim 3, wherein at least one of the following (+) norcisapride and the proton pump inhibitor are administered orally.
18. The method of claim 17, wherein it is administered orally (+) norcisapride and pump • protons [sic] as a tablet or capsule.
19. The method of claim 3, wherein at least one of the following is administered orally: (+) norcisapride and the H2 receptor antagonist.
The method of claim 3, wherein a proton pump inhibitor or H2 receptor antagonist is administered together with (+) norcisapride parenterally, transdermally, straightly or sublingually.
21. The method of claim 3, which consists of administering the proton pump inhibitor or the H2 receptor antagonist, and (+) norcisapride, concurrently or in sequence.
22. A method for treating gastrointestinal motility dysfunction in a patient, which consists of administering to the patient an effective therapeutic amount of (+) norcisapride, or one of its salts 25 acceptable pharmaceutics, substantially free of its stereoisomer (-) and an effective therapeutic amount of at least one of the following: a proton pump inhibitor, a receptor antagonist for H2, or an optically pure stereoisomer or an active metabolite of these, or an acceptable pharmaceutical salt thereof.
23. A method for treating emesis in a patient, which consists of administering to the patient in need of such prevention, treatment or management, an effective therapeutic amount of (+) norcisapride, or one of its acceptable pharmaceutical salts, substantially free of its stereoisomer ( -) and an effective therapeutic amount of at least one of the following: a proton pump inhibitor, an H2 receptor antagonist, or an optically pure stereoisomer or an active metabolite thereof, or an acceptable pharmaceutical salt thereof .
24. A method for treating gastroesophageal reflux disease in a patient, which is to administer an effective therapeutic amount of (+) norcisapride, or one of its acceptable pharmaceutical salts, substantially free of its stereoisomer (-) and an effective therapeutic amount of at least one of the following: a proton pump inhibitor, a receptor antagonist for H2 or a • optically pure stereoisomer or an active metabolite thereof, or an acceptable pharmaceutical salt thereof.
25. A method for treating gastroesophageal reflux disease in a patient, which consists of administering to the patient in need of such treatment, ^^ an effective therapeutic amount of: (a) cisapride, or a 10 of its acceptable pharmaceutical salts or an optically pure stereoisomer thereof; (b) ondansetron, or one of its acceptable pharmaceutical salts or an optically pure stereoisomer thereof; and (c) an effective therapeutic amount of at least one of the following: 15 proton pump inhibitor, a receptor antagonist for H, or an optically pure stereoisomer or an active metabolite thereof, or an acceptable pharmaceutical salt thereof.
26. The method of claim 25, wherein (+) optically pure cisapride or optically pure (-) cisapride, or one of its pharmaceutically acceptable salts is administered.
27. The method of claim 25 or 26, wherein optically pure R (+) ondansetron is administered.
28. The method of claim 25, wherein the proton pump inhibitor being administered is selected from the group consisting of omeprazole, lanzoprazole, pantoprazole, rabeprazole, hydroxy-omeprazole, hydroxy-lazoprazole, the carboxyl derivative of omeprazole, and desmethyl. -pantoprazole
29. The method of claim 25, wherein the amount of the proton pump inhibitor that is administered is from about 1 mg to about 200 mg.
30. The method of claim 25, wherein the H2-receptor antagonist that is administered is selected from the group consisting of cimetidine, famotidine, ranitidine, nizatidine and N2-demethylnizatidine.
31. The method of claim 25, wherein the amount of H2 receptor antagonist that is administered is from about 1 mg to about 240 mg.
32. The method of claim 25, wherein at least one of the following is administered orally: (+) optically pure cisapride, (-) optically pure cisapride, optically pure R (+) ondansetron, and the inhibitor of the protons
33. The method of claim 25, wherein at least one of the following is administered orally: cisapride, optically pure R (+) ondansetron and the H2 receptor antagonist.
34. A method for the prevention or management of gastrointestinal disorders in a patient, which consists of administering to the patient in need of prevention or management an effective therapeutic amount of an antagonist for 5-HT3, an agonist for 5-HT4 and at least one of the following: a receptor antagonist for H2 or a proton pump inhibitor, or an optically pure stereoisomer or active metabolite thereof, or an acceptable pharmaceutical salt thereof.
35. A method for the prevention or management of gastrointestinal disorders in a patient, which consists of administering an effective therapeutic amount of an agent or compound acting on the receptors for 5-HT3 and the receptors for 5-HT4, and a therapeutic amount effective of at least one of the following: a proton pump [sic] or an H2 receptor [sic], or an optically pure stereoisomer or active metabolite thereof, or an acceptable pharmaceutical salt thereof.
36. A method for the prevention or management of gastrointestinal disorders in a patient, which consists of administering to the patient an effective therapeutic amount of (+) norcisapride, or one of its acceptable pharmaceutical salts, substantially free of its stereoisomer (-), and a The effective therapeutic amount of at least one of the following: a proton pump inhibitor, an H2 receptor antagonist, or an optically pure stereoisomer or an active metabolite thereof, or an acceptable pharmaceutical salt thereof.
37. A method for the prevention or management of gastrointestinal motility dysfunction in a patient, which consists of administering to the patient an effective therapeutic amount of (+) norcisapride, or an acceptable pharmaceutical salt thereof, substantially free of its stereoisomer (- ) and an effective therapeutic amount of at least one of the following: a proton pump inhibitor, an H2 receptor antagonist, or an optically pure stereoisomer or an active metabolite thereof, or an acceptable pharmaceutical salt thereof.
38. A method for the prevention or management of emesis in a patient, which consists in administering to the patient in need of such prevention, treatment or management, an effective therapeutic amount of (+) norcisapride, or an acceptable pharmaceutical salt thereof, substantially without its stereoisomer (-) and an effective therapeutic amount of at least one of the following: a proton pump inhibitor, an H2 receptor antagonist, or an optically pure stereoisomer or an active metabolite thereof, or a pharmaceutical salt acceptable of these.
39. A method for the prevention or management of gastroesophageal reflux disease in a patient, which consists of administering an effective therapeutic amount of (+) norcisapride, or an acceptable pharmaceutical salt thereof, substantially without its stereoisomer (-) and a therapeutic amount effective of at least one of the following: a proton pump inhibitor, an H2 receptor antagonist, or an optically pure stereoisomer or an active metabolite thereof, or an acceptable pharmaceutical salt thereof.
40. A method for the prevention or management of gastroesophageal reflux disease in a patient, which consists in administering to the patient in need of such prevention or management an effective therapeutic amount of: (a) cisapride, or an optically pure stereoisomer or a pharmaceutical salt acceptable from this one; (b) ondansetron, or an acceptable pharmaceutical salt or an optically pure stereoisomer thereof; and (c) an effective therapeutic amount of at least one of the following: a proton pump inhibitor, a receptor antagonist for H2, or an optically pure stereoisomer or an active metabolite thereof, or an acceptable pharmaceutical salt of these.
41. The method of claim 40, wherein (+) pure cisapride or optically pure (-) cisapride, or an acceptable pharmaceutical salt thereof is administered.
42. The method of claim 40, wherein optically pure R (+) ondansetron, or an acceptable pharmaceutical salt thereof, is administered.
43. The method of claim 40, wherein the administered proton pump inhibitor is selected from the group consisting of omeprazole, lansoprazole, pantoprazole, rabeprazole, hydroxy-omeprazole, hydroxylansoprazole, the carboxylic acid derivative of omeprazole, and desmethyl pantoprazole .
44. The method of claim 40, wherein the amount of the proton pump inhibitor that is administered is from about 1 mg to about 200 mg.
45. The method of claim 40, wherein the H2 receptor antagonist that is administered is selected from the group consisting of cimetidine, famotidine, ranitidine, nizatidine and N2-demethysizidine.
46. The method of claim 40, wherein the amount of the H2 receptor antagonist that is administered is from about 1 mg to about 2400 mg.
47. The method of claim 40, wherein at least one of: cisapride, R (+) ondansetron, and the proton pump inhibitor is administered orally.
48. The method of claim 40, wherein at least one of: cisapride, R (+) ondansetron, and the H2 receptor antagonist is administered orally.
49. A pharmaceutical composition adapted for the treatment of a patient suffering from gastrointestinal disorder, which comprises an effective therapeutic amount of (+) norcisapride, or one of its acceptable pharmaceutical salts, substantially free of its stereoisomer (-); and an effective therapeutic amount of at least one of the following: a proton pump inhibitor, an H2 receptor antagonist, or an optically pure stereoisomer or an active metabolite thereof, or an acceptable pharmaceutical salt thereof.
50. The composition of claim 49, wherein the proton pump inhibitor is present and is selected from the group consisting of omeprazole, pantoprazole, rabeprazole, lansoprazole, hydroxy-omeprazole, hydroxylansoprazole, the carboxylic acid derivative of omeprazole and desmethyl pantoprazole
51. The pharmaceutical composition of claim 49, wherein the H2 receptor antagonist is present and is selected from the group consisting of cimetidine, famotidine, ranitidine, nizatidine and N2-demethylnizatidine.
52. A pharmaceutical composition adapted for the treatment of a patient suffering from a gastrointestinal disorder, which comprises: (a) an effective therapeutic amount of an optically pure stereoisomer of cisapride, or an acceptable pharmaceutical salt thereof; (b) an effective therapeutic amount of optically pure T (+) ondansetron, or an acceptable pharmaceutical salt thereof; and (c) an effective therapeutic amount of at least one of the following: a proton pump inhibitor, a receptor antagonist for H2, or an optically pure stereoisomer or an active metabolite thereof, or an acceptable pharmaceutical salt of these.
53. The pharmaceutical composition of claim 52, wherein the proton pump inhibitor is present and is selected from the group consisting of omeprazole, pantoprazole, rabeprazole, lansoprazole, hydroxy-omeprazole, hydroxylansoprazole, the carboxylic acid derivative of omeprazole and Desmethyl pantoprazole
54. The pharmaceutical composition of claim 52, wherein the H2 receptor antagonist is present and is selected from the group consisting of cimetidine, ranitidine, famotidine, nizatidine and N2-demethylnizatidine.
55. The method of claim 12, wherein the proton pump inhibitor is optically pure (+) pantoprazole, (-) optically pure pantoprazole, (+) optically pure rabeprazole, (-) optically pure rabeprazole, (+) optically pure lansoprazole, (-) optically pure lansoprazole, (+) optically pure omeprazole or optically pure (-) omeprazole.
56. The pharmaceutical composition of claim 50 or 53, wherein the proton pump inhibitor is optically pure (+) pantoprazole, (-) optically pure pantoprazole, (+) optically pure rabeprazole, (-) optically pure rabeprazole, (+) ) optically pure lansoprazole, (-) optically pure lansoprazole, (+) optically pure omeprazole or optically pure (-) omeprazole.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/122,394 | 1999-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA01008805A true MXPA01008805A (en) | 2002-05-09 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6362202B1 (en) | Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists | |
AU780579B2 (en) | Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists | |
EP1089733B1 (en) | Use of optically pure (+)-norcisapride for treating irritable bowel syndrome | |
AU720407B2 (en) | Optically pure (-) norcisapride for treating digestive tract disorders | |
EP0896539B1 (en) | Use of optically pure (+) norcisapride for treating emesis and central nervous system disorders | |
AU717396B2 (en) | Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders | |
CA2139636A1 (en) | Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders | |
US6147093A (en) | Methods for treating gastroesophageal reflux disease | |
EP1087765B1 (en) | Use of optically pure (-) norcisapride in the treatment of irritable bowel syndrome | |
MXPA01008805A (en) | Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or h2 | |
MXPA01008806A (en) | Methods and compositions using (-) norcisapride in combination with proton pump inhibitors or h2 | |
AU780107B2 (en) | Methods for treating emesis and central nervous system disorders using optically pure () norcisapride |